En español
NIDA

Population Assessment of Tobacco and Health (PATH) Study

Revised October 2018

What is the PATH Study?

The Population Assessment of Tobacco and Health (PATH) Study is a nationally representative longitudinal study of tobacco use and health in the United States. A collaboration between the National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) and the U.S. Food and Drug Administration (FDA) Center for Tobacco Products, the study was launched in 2011, started the first wave of data collection in 2013, and completed its fourth wave in late 2017.

Science Spotlight: E-cig ads and cigarette smoking in youth (March 26, 2018)

By following study participants over time, the PATH Study helps scientists learn how and why people start using tobacco products, quit using them, and start using them again after they’ve quit, as well as how different tobacco products affect health outcomes (such as cardiovascular and respiratory health) over time. Most participants complete the study questionnaire every other year.

The National Institutes of Health (NIH) and the Food and Drug Administration (FDA) announce the release of data files from the Population Assessment of Tobacco and Health (PATH) Study. The PATH Study is a household-based, nationally representative, longitudinal cohort study of youth (12-17 years old) and adults in the United States. The study was launched in 2011 to inform FDA’s regulatory activities under the Family Smoking Prevention and Tobacco Control Act. For more information on the PATH Study, please visit: http://doi.org/10.3886/Series606.  

Updates in the latest release include:

Wave 3 Public Use Files (PUF)
Public-use questionnaire data files (PUFs) from the third wave of the PATH Study may be downloaded from the National Addiction & HIV Data Archive Program (NAHDAP) of the Inter-university Consortium for Political and Social Research (ICPSR). Data in the third wave were collected from October 2015 to October 2016. For information on the Wave 3 PUF, please visit: https://doi.org/10.3886/ICPSR36498.

Wave 1 Biomarker Restricted Use File (BRUF) Update
Data and documentation for five Wave 1 Biomarkers of Potential Harm assay panels were added to the PATH Study Biomarker Restricted-Use Files (BRUF) including:

  1. F2PG2a: oxidative stress biomarker (8-isoprostane)
  2. hsCRP: high-sensitivity C-reactive protein
  3. IL6: interleukin 6
  4. sICAM: soluble Intercellular Adhesion Molecule 1
  5. Fibro: fibrinogen activity (Clauss)

The updated files were added to the existing biomarkers of tobacco exposure data in the Biomarker RUF, which include measurements of arsenic, creatinine, metals, polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, nicotine metabolites, and volatile organic compounds in urine and measurements of cotinine and hydroxycotinine in serum. Qualified researchers may apply for access to the PATH BRUF at: https://doi.org/10.3886/ICPSR36840.

Researchers interested in the PATH Study are encouraged to join the PATH Study Data User Forum at: https://pathstudyforum.icpsr.umich.edu/.

The forum enables researchers using PATH Study data to submit and answer questions. Announcements, data releases and updates, new publications, upcoming events, and other information for PATH Study data users are also posted to the forum. 

Please share this information with others who may be interested.

Study Team

Scientists at NIDA and the FDA are leading the PATH Study. They are working with Westat, a research company with expertise in survey design, questionnaire development, data collection, and analysis. Westat also manages a team of partner organizations working on the Study.

The Principal Investigator of the PATH Study is located at Roswell Park Comprehensive Cancer Center. Other participating scientists are from:

Goals

By monitoring and assessing behaviors, attitudes, biomarkers, and health outcomes associated with tobacco use in the United States, the PATH Study helps enhance the evidence base informing FDA’s regulatory activities related to tobacco. Specifically, the study aims to:

  • Examine susceptibility to tobacco product use;
  • Study the progression of tobacco product use, including initiation, dependence, cessation, and relapse;
  • Evaluate patterns of tobacco use, including:
    • use of newer products, such as e-cigarettes or ENDS (electronic nicotine delivery systems);
    • poly-use;
    • switching products;
  • Track potential behavioral and health impacts, including biomarkers of exposure and potential harm; and
  • Assess differences in tobacco-related attitudes, behaviors, and health conditions among racial/ethnic, gender, and age subgroups over time.

Initial Findings

About 46,000 people aged 12 years and older, including tobacco users and non-users, were included in the first wave of the PATH Study.

Initial data on adult and youth tobacco use, published January 2017 in the New England Journal of Medicine, showed that more than 25 percent of American adults were current users of tobacco in 2013-14 and roughly 9 percent of youth reported using tobacco in the past 30 days. Multiple product use was common among tobacco users, accounting for roughly 40 percent of adult and youth tobacco users, with cigarettes and e-cigarettes being the most common combination among both age groups.

Among tobacco users who reported using more than one product:

  • 23 percent of adults and 15 percent of youth used cigarettes and e-cigarettes
  • 6 percent of adults and 4 percent of youth used cigarettes and hookah
  • 2 percent of adults and 5 percent of youth used e-cigarettes and hookah
  • 5 percent of adults and 10 percent of youth used cigarettes and cigarillos

The study reports prevalence for additional product combinations used by study participants.

Data Access

Data and documentation (questionnaires, codebooks) related to the PATH Study are available at the study website at the National Addiction & HIV Data Archive Program (NAHDAP), including instructions for access to restricted- and public-use files:

Data from additional waves will be released as they become available.

Biospecimen Access Program (BAP)

Biospecimens collected from PATH Study participants are also available to the research community. Investigators proposing meritorious and feasible studies consistent with PATH Study objectives or research priorities for tobacco regulatory science will be given highest priority for access to these biospecimens. Proposals addressing other objectives that advance the knowledge of tobacco use or tobacco-related health outcomes will also be considered. There are two submission and review cycles per year, beginning in September and May. Application instructions and deadlines are available at the PATH Study webpage on the NAHDAP website:

Journal Publications

Listed below is a selection of peer-reviewed journal articles using data from the PATH Study. See the PATH Study website at NAHDAP or search PubMed.gov for a complete list of publications.

Additional Resources

Questions?

Contact PATHStudyinfo@westat.com.

This page was last updated October 2018